PMG Staff, Author at Precision Medicine Group

Precision for Value Acquires Redwood Outcomes

PMG Staff2015-11-04T11:50:37-05:00News, Press Releases|

Extends Leadership and Global Reach in Health Economics and Outcomes Research

Gladstone, N.J. and Vancouver, B.C., November 4, 2015 – Precision for Value (Precision) today announced that it has acquired Redwood Outcomes, a leading international health economics and outcomes research (HEOR) company. Redwood Outcomes serves pharmaceutical and biotechnology companies and applies the science of evidence generation, synthesis, and modeling to optimize healthcare decision making.

(more…)

Commentary: How to Evaluate the Opportunity of Indication-Based Drug Contracting

PMG Staff2020-07-23T16:15:36-04:00Thought Leadership|

Precision for Value’s Jeremy Schafer discusses the concept of indication-based drug contracting and how it could represent a new frontier of manufacturer-payer agreements.

Commentary: Understanding Health Care’s Short-Termism Problem

PMG Staff2020-07-23T16:15:37-04:00Thought Leadership|

Precision’s Chief Scientific Officer Amitabh Chandra and PHE founding partner Dana Goldman address health care’s Short-Termism problem in their latest article for the Harvard Business Review.

Sandoz’ Filgrastim Biosimilar Is Now on the US Market – Pharmaceutical Commerce Magazine

PMG Staff2015-09-04T14:43:36-04:00News|

Precision for Medicine’s Larry Blandford quoted in an article from Pharmaceutical Commerce magazine on a new biosimilar product from Novartis’ Sandoz unit called Zarxio.

Commentary: World Returns in Health Care Will Drive How Long You Live, But Your Country Will Stand in Your Way

PMG Staff2020-07-23T16:15:37-04:00Thought Leadership|

Tomas Philipson’s latest Forbes.com Op-Ed examines how international linkages between health care economies will affect how long you and your kids will live.

Precision’s MacEwan Participates in The Network for Excellence in Health Innovation (NEHI) “On Call” Series

PMG Staff2015-08-19T14:29:30-04:00News|

The Network for Excellence in Health Innovation (NEHI) held a special forum on August 19th, focusing on better use of medicines in diabetes, featuring the recent study and ADA presentation by Precision’s Joanna MacEwan. She discussed her recent work and fielded questions from the NEHI membership– exploring the implications of new research on the use of diabetes medications and what it means for health care delivery reform, insurance benefit design, changes in health care payment and other critical policy issues.

Commentary: Dying to Live – Why Is Health Care So Valuable in the Face of Death?

PMG Staff2020-07-23T16:15:37-04:00Thought Leadership|

Tomas Philipson’s latest Forbes.com Op-Ed examines end of life care, and why health care is so valuable in the face of death.

Commentary: Big Data Analytics: The Next Evolution in Drug Development

PMG Staff2020-07-23T16:15:37-04:00Thought Leadership|

Precision’s Deb Phippard, PhD, and Jared Kohler, PhD, address the potential of Big Data, analytics, and technology to increase efficiency and decrease costs in the drug development process in a guest column for Bioprocess Online. Read the full article here:

Commentary: The California Child Vaccination Mandates and the Everlasting Cycle of Infectious Diseases

PMG Staff2020-07-23T16:15:37-04:00Thought Leadership|

Precision’s Tomas Philipson’s latest Forbes.com Op-Ed examines California’s recently enacted vaccination mandate, and the application of economic epidemiology.

Precision for Value Adds Prominent Health Economist Dr. Christopher Blanchette to its Expanding HEOR Team

PMG Staff2015-07-08T11:48:40-04:00News, Press Releases|

NEW YORK, July 8, 2015 – Precision for Value (www.precisionforvalue.com), a Precision for Medicine Company which provides health economics, analytics, and marketing communications services to life sciences clients, today announced the further expansion of its Health Economics and Outcomes Research (HEOR) team to meet growing customer demand. Christopher Blanchette, PhD, was appointed Vice President, Health Economics.

(more…)

News & Insights

About PMG Staff

Precision for Value Acquires Redwood Outcomes

Commentary: How to Evaluate the Opportunity of Indication-Based Drug Contracting

Commentary: Understanding Health Care’s Short-Termism Problem

Sandoz’ Filgrastim Biosimilar Is Now on the US Market – Pharmaceutical Commerce Magazine

Commentary: World Returns in Health Care Will Drive How Long You Live, But Your Country Will Stand in Your Way

Precision’s MacEwan Participates in The Network for Excellence in Health Innovation (NEHI) “On Call” Series

Commentary: Dying to Live – Why Is Health Care So Valuable in the Face of Death?

Commentary: Big Data Analytics: The Next Evolution in Drug Development

Commentary: The California Child Vaccination Mandates and the Everlasting Cycle of Infectious Diseases

Precision for Value Adds Prominent Health Economist Dr. Christopher Blanchette to its Expanding HEOR Team

News & Insights

The global impact of Precision Medicine Group. As it happens.

About PMG Staff